PMID- 25553913
OWN - NLM
STAT- MEDLINE
DCOM- 20150918
LR  - 20220311
IS  - 1744-7682 (Electronic)
IS  - 1471-2598 (Linking)
VI  - 15
IP  - 4
DP  - 2015 Apr
TI  - Potential approaches for more successful dendritic cell-based immunotherapy.
PG  - 569-82
LID - 10.1517/14712598.2015.1000298 [doi]
AB  - INTRODUCTION: Dendritic cells (DCs) are the most important antigen-presenting 
      cell population for activating antitumor T-cell responses; therefore, they offer 
      a unique opportunity for specific targeting of tumors. AREAS COVERED: We will 
      discuss the critical factors for the enhancement of DC vaccine efficacy: 
      different DC subsets, types of in vitro DC manufacturing protocol, types of tumor 
      antigen to be loaded and finally different adjuvants for activating them. We will 
      cover potential combinatorial strategies with immunomodulatory therapies: 
      depleting T-regulatory (Treg) cells, blocking VEGF and blocking inhibitory 
      signals. Furthermore, recommendations to incorporate these criteria into DC-based 
      tumor immunotherapy will be suggested. EXPERT OPINION: Monocyte-derived DCs are 
      the most widely used DC subset in the clinic, whereas Langerhans cells and 
      plasmacytoid DCs are two emerging DC subsets that are highly effective in 
      eliciting cytotoxic T lymphocyte responses. Depending on the type of tumor 
      antigens selected for loading DCs, it is important to optimize a protocol that 
      will generate highly potent DCs. The future aim of DC-based immunotherapy is to 
      combine it with one or more immunomodulatory therapies, for example, Treg cell 
      depletion, VEGF blockage and T-cell checkpoint blockage, to elicit the most 
      optimal antitumor immunity to induce long-term remission or even cure cancer 
      patients.
FAU - Chiang, Cheryl Lai-Lai
AU  - Chiang CL
AD  - University of Pennsylvania Medical Center, Ovarian Cancer Research Center , 
      Philadelphia, PA 19104 , USA Lana.Kandalaft@chuv.ch ; cheryl_chiang@yahoo.com.
FAU - Balint, Klara
AU  - Balint K
FAU - Coukos, George
AU  - Coukos G
FAU - Kandalaft, Lana E
AU  - Kandalaft LE
LA  - eng
GR  - P01-CA83638/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20150102
PL  - England
TA  - Expert Opin Biol Ther
JT  - Expert opinion on biological therapy
JID - 101125414
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Animals
MH  - CD8-Positive T-Lymphocytes/immunology/transplantation
MH  - Cancer Vaccines/immunology/therapeutic use
MH  - Cell- and Tissue-Based Therapy/*methods/trends
MH  - Dendritic Cells/immunology/*transplantation
MH  - Humans
MH  - Immunotherapy/*methods/trends
MH  - Monocytes/immunology/transplantation
MH  - Neoplasms/immunology/therapy
MH  - T-Lymphocytes, Cytotoxic/immunology/transplantation
MH  - T-Lymphocytes, Regulatory/immunology/transplantation
OTO - NOTNLM
OT  - cancer
OT  - dendritic cell
OT  - immunotherapy
OT  - vaccines
EDAT- 2015/01/03 06:00
MHDA- 2015/09/19 06:00
CRDT- 2015/01/03 06:00
PHST- 2015/01/03 06:00 [entrez]
PHST- 2015/01/03 06:00 [pubmed]
PHST- 2015/09/19 06:00 [medline]
AID - 10.1517/14712598.2015.1000298 [doi]
PST - ppublish
SO  - Expert Opin Biol Ther. 2015 Apr;15(4):569-82. doi: 10.1517/14712598.2015.1000298. 
      Epub 2015 Jan 2.